Last reviewed · How we verify
Osteoarthritis in Patients at High Ulcer Risk
Approved treatments
- Voltaren · Hisamitsu Pharmaceutical Co., Inc
- Nexium · AstraZeneca
- Cytotec · Pfizer
Diclofenac inhibits COX-1/COX-2 to reduce prostaglandins; misoprostol is PGE1 analog protecting gastric mucosa. - Arthrotec · Pfizer
- Cytotec · Generic (originally Searle/Pfizer)
Synthetic prostaglandin E1 analog that protects gastric mucosa by inhibiting acid secretion and stimulating mucus/bicarbonate, also causes uterine contraction.
Clinical guidelines
- FDA label — 1L
Diclofenac sodium and misoprostol delayed-release tablets are indicated for the treatment of the signs and symptoms of osteoarthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. - FDA label — 1L
Diclofenac sodium and misoprostol delayed-release tablets are indicated for the treatment of the signs and symptoms of rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Osteoarthritis in Patients at High Ulcer Risk patent landscape — cliff calendar, originator estates, attackable patents
- Osteoarthritis in Patients at High Ulcer Risk treatment landscape brief
- Osteoarthritis in Patients at High Ulcer Risk treatment updates RSS
Frequently asked questions about Osteoarthritis in Patients at High Ulcer Risk
What drugs treat Osteoarthritis in Patients at High Ulcer Risk?
Tracked treatments include Voltaren, Nexium, Cytotec, Arthrotec.
What is the treatment for Osteoarthritis in Patients at High Ulcer Risk?
Standard treatment for Osteoarthritis in Patients at High Ulcer Risk includes Voltaren, Nexium, Cytotec, Arthrotec. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Osteoarthritis in Patients at High Ulcer Risk?
FDA label publishes guidelines for Osteoarthritis in Patients at High Ulcer Risk. 2 guideline references tracked.
Related
- Treatment landscape: Osteoarthritis in Patients at High Ulcer Risk patent cliff · Osteoarthritis in Patients at High Ulcer Risk CI report
- Treatment: Voltaren · Hisamitsu Pharmaceutical Co., Inc
- Treatment: Nexium · AstraZeneca
- Treatment: Cytotec · Pfizer
- Treatment: Arthrotec · Pfizer
- Treatment: Cytotec · Generic (originally Searle/Pfizer)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing